Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASHGlobeNewsWire • 01/29/20
FDA Decision For Intercept's NASH Drug Ocaliva Delayed; Opportunity Presents ItselfSeeking Alpha • 01/20/20
Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The LancetGlobeNewsWire • 12/06/19
Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/19
This Biotech Flew To A 7-Month High On A Double Serving Of Good NewsInvestors Business Daily • 11/25/19